Form 4: Apellis CSO Sells Shares for Tax Withholding

Apellis Pharmaceuticals' Chief Scientific Officer, Pascal Deschatelets, sold 5,928 shares of common stock to cover tax withholding obligations.

Summary

• Pascal Deschatelets, Chief Scientific Officer of Apellis Pharmaceuticals, Inc. (APLS), reported a transaction on January 22, 2026.
• The transaction involved the sale of 5,928 shares of Apellis common stock.
• The shares were sold at a price of $21.7654 per share.
• The purpose of the sale was to cover tax withholding obligations related to Restricted Stock Units (RSUs) released on January 21, 2026.
• Following this transaction, Deschatelets beneficially owns 1,151,382 shares of common stock directly.

Sentiment

Score: 5

Explanation: The transaction is a routine sale to cover tax obligations on RSU vesting, which is a neutral event and does not indicate positive or negative sentiment towards the company's prospects.

Industry Context

This Form 4 filing details a routine insider transaction for tax purposes, which is a common occurrence across all industries, including the biotechnology and pharmaceutical sector where Apellis Pharmaceuticals operates. It does not provide insights into broader industry trends or competitive positioning.

Stakeholder Impact

• Shareholders: Minimal direct impact as this is a routine, tax-related sale by an insider and not indicative of a change in confidence or significant divestment.

Key Dates

Keywords

Apellis Pharmaceuticals, APLS, Pascal Deschatelets, Chief Scientific Officer, Insider Trading, Form 4, Stock Sale, Tax Withholding, Restricted Stock Units